Horizon Therapeutics USA Inc.
- Address
- 1 Horizon Way
Sponsor Overview
Specializations
Thyroid Eye Disease
Horizon Therapeutics USA Inc. focuses on clinical research in thyroid eye disease, with attention to both moderate-to-severe active thyroid eye disease and broader disease management in adult patients.
- Proptosis
- Ocular inflammation
- Orbital disease
The sponsor’s studies center on outcomes relevant to eye prominence, symptom control, and disease activity in this autoimmune condition.
Ophthalmic Autoimmune Disorders
The research portfolio includes therapeutic interest in autoimmune conditions affecting the orbit and surrounding tissues, with emphasis on clinical manifestations that impair vision and eye function.
- Autoimmune orbital disease
- Extraocular tissue involvement
- Eye discomfort
These studies reflect a clinical focus on disease-specific ophthalmic outcomes and patient-centered symptom burden.
Biologic Therapy in Endocrine-Related Eye Disease
Horizon Therapeutics USA Inc. is active in research evaluating teprotumumab for endocrine-related eye disease, with interest in treatment response and durability of effect.
- IGF-1 receptor inhibition
- Therapeutic response
- Retreatment need
The company’s clinical work in this area addresses the role of targeted biologic therapy in reducing disease activity and improving orbital outcomes.
Adult Patient Treatment Outcomes
The sponsor’s trials involve adult male and female participants, with attention to treatment tolerability, safety, and clinical benefit in a chronic ophthalmic condition.
- Tolerability
- Safety
- Clinical response
Research activity in this area is directed toward defining practical therapeutic use in adults affected by active eye disease.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Safety, and Tolerability of Subcutaneous Teprotumumab in Moderate-to-Severe Active Thyroid Eye Disease: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Trial |  France Germany Italy Poland Spain | Not Yet Recruiting |
| Evaluation of Safety and Tolerability of Teprotumumab Dosing Durations in Patients with Thyroid Eye Disease: A Phase 3b/4 Randomized, Double-Masked, Multicenter Trial | France Germany Italy Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 23 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases2 trials138 other sponsors
Partnered Research Centres
23 centres- Address
- Piazza Santa Maria Di Gesu, 95123 Catania
- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Via Sergio Pansini 5, 80131 Naples
- Address
- Via Paradisa 2, 56124 Pisa
- Address
- Viale Luigi Borri N 57, 21100 Varese
- Address
- 3 Boulevard Alexandre Fleming, 25000 Besançon
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Horizon Therapeutics USA Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.